Christopher L Corless

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Oncogene 23:7780-90. 2004
  2. ncbi request reprint Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall
    Maggie M Lam
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Int J Gynecol Pathol 25:288-92. 2006
  3. doi request reprint Tackling formalin-fixed, paraffin-embedded tumor tissue with next-generation sequencing
    Christopher L Corless
    Department of Pathology, and Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
    Cancer Discov 2:23-4. 2012
  4. pmc KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors
    Christopher L Corless
    Department of Pathology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Mol Diagn 6:366-70. 2004
  5. ncbi request reprint Molecular pathobiology of gastrointestinal stromal sarcomas
    Christopher L Corless
    Department of Pathology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Annu Rev Pathol 3:557-86. 2008
  6. pmc Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia
    Christopher L Corless
    OHSU Dept of Pathology L471, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    J Mol Diagn 8:604-12. 2006
  7. ncbi request reprint PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib
    Christopher L Corless
    Department of Pathology, Division of Hematology and Oncology, Oregon Health and Science University Cancer Institute, Portland, OR 97201, USA
    J Clin Oncol 23:5357-64. 2005
  8. pmc Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
    Michael C Heinrich
    Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Clin Oncol 26:5352-9. 2008
  9. doi request reprint Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Charles D Blanke
    Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
    J Clin Oncol 26:620-5. 2008
  10. ncbi request reprint Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003

Detail Information

Publications105 found, 100 shown here

  1. ncbi request reprint Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Oncogene 23:7780-90. 2004
    ..These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated...
  2. ncbi request reprint Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall
    Maggie M Lam
    Department of Anatomic Pathology, University of Washington Medical Center, Seattle, WA 98195, USA
    Int J Gynecol Pathol 25:288-92. 2006
    ..Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum...
  3. doi request reprint Tackling formalin-fixed, paraffin-embedded tumor tissue with next-generation sequencing
    Christopher L Corless
    Department of Pathology, and Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
    Cancer Discov 2:23-4. 2012
    ..A new study by Wagle and colleagues shows that a combination of hybridization-capture and deep sequencing yields high-quality data from FFPE specimens...
  4. pmc KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors
    Christopher L Corless
    Department of Pathology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Mol Diagn 6:366-70. 2004
    ..Laboratories that offer clinical screening for KIT mutations in GI stromal tumors should be aware of this class of mutations...
  5. ncbi request reprint Molecular pathobiology of gastrointestinal stromal sarcomas
    Christopher L Corless
    Department of Pathology, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Annu Rev Pathol 3:557-86. 2008
    ....
  6. pmc Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia
    Christopher L Corless
    OHSU Dept of Pathology L471, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    J Mol Diagn 8:604-12. 2006
    ..Thus, the assay may be useful in confirming the diagnosis of SM...
  7. ncbi request reprint PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib
    Christopher L Corless
    Department of Pathology, Division of Hematology and Oncology, Oregon Health and Science University Cancer Institute, Portland, OR 97201, USA
    J Clin Oncol 23:5357-64. 2005
    ..Little is known of the other types of PDGFRA mutations that occur in GISTs...
  8. pmc Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
    Michael C Heinrich
    Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Clin Oncol 26:5352-9. 2008
    ..We evaluated the impact of primary and secondary kinase genotype on sunitinib activity...
  9. doi request reprint Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Charles D Blanke
    Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
    J Clin Oncol 26:620-5. 2008
    ..We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status...
  10. ncbi request reprint Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003
    ..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
  11. ncbi request reprint Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)
    Anette Duensing
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 64:5127-31. 2004
    ..PKCtheta is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target...
  12. ncbi request reprint The gene expression profile of extraskeletal myxoid chondrosarcoma
    Subbaya Subramanian
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94035, USA
    J Pathol 206:433-44. 2005
    ..Small molecule inhibitors for PPARG exist and PPARG could be a potential therapeutic target for EMC...
  13. ncbi request reprint Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
    Michael C Heinrich
    Division of Hematology Oncology, Department of Pathology, Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    J Clin Oncol 24:4764-74. 2006
    ..In clinical studies, 75% to 90% of patients with advanced GISTs experience clinical benefit from imatinib. However, imatinib resistance is an increasing clinical problem...
  14. ncbi request reprint Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
    Michael C Heinrich
    Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR, USA
    J Clin Oncol 24:1195-203. 2006
    ..To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent...
  15. doi request reprint Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
    Michael C Heinrich
    Department of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 14:2717-25. 2008
    ..To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases...
  16. pmc Determination of stromal signatures in breast carcinoma
    Robert B West
    Department of Pathology, Stanford University Medical Center, Stanford, California, USA
    PLoS Biol 3:e187. 2005
    ..Our findings suggest that the host stromal response varies significantly among carcinomas and that gene expression patterns characteristic of soft tissue tumors can be used to discover new markers for normal connective tissue cells...
  17. pmc Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr
    Michael C Heinrich
    Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Clin Oncol 26:5360-7. 2008
    ..In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing...
  18. doi request reprint Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes
    Bernadette Liegl
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 33:437-46. 2009
    ..DOG1.1 is also a sensitive marker for unusual GIST subgroups lacking KIT or PDGFRA mutations. In tumors that are negative for both KIT and DOG1.1, mutational screening may be required to confirm the diagnosis of GIST...
  19. ncbi request reprint KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications
    Fabiola Medeiros
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 28:889-94. 2004
    ..Notably, some KIT-negative GISTs contain imatinib-sensitive KIT or PDGFRA mutations; therefore, patients with KIT-negative GISTs should not, a priori, be denied imatinib therapy...
  20. doi request reprint High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast
    Megan L Troxell
    Department of Pathology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Mod Pathol 23:27-37. 2010
    ..These findings indicate that approximately two-thirds of papillomas are driven by mutations in the PI3CA/AKT pathway. Some papillary carcinomas may arise from these lesions, but others may have different molecular origins...
  21. doi request reprint Leiomyoma of the gastrointestinal tract with interstitial cells of Cajal: a mimic of gastrointestinal stromal tumor
    Anita Deshpande
    Department of Pathology and Laboratory Medicine, Boston Medical Center Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA Department of Pathology, Oregon Health and Science University, Portland, OR
    Am J Surg Pathol 38:72-7. 2014
    ..ICCs are also identified in gastric and intestinal LMs, albeit in a smaller proportion of cases. Colonization and hyperplasia by non-neoplastic ICCs likely account for this phenomenon. ..
  22. doi request reprint Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation
    Kevin B Long
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 34:907-12. 2010
    ..This seems to be the first EGIST arising above the diaphragm. This case shows a potential diagnostic pitfall with therapeutic consequences...
  23. doi request reprint Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression
    Bernadette Liegl
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 33:218-26. 2009
    ..The rhabdomyoblastic differentiation can represent a diagnostic pitfall. The molecular mechanisms for this form of TKI-resistant clonal evolution remain to be determined...
  24. doi request reprint A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors
    Inigo Espinosa
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Am J Surg Pathol 32:210-8. 2008
    ..5%) synovial sarcomas among the 935 soft tissue tumors examined showed positive immunostaining for DOG1.1. In addition, DOG1.1 immunoreactivity was seen in fewer cases of carcinoma, melanoma, and seminoma as compared with KIT...
  25. pmc Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis
    Gangwen Han
    Department of Otolaryngology, Oregon Health and Science University, Portland, OR, USA
    J Clin Invest 115:1714-23. 2005
    ..TGF-beta1-mediated EMT requires functional TGF-(beta)RII, whereas TGF-beta1-mediated tumor invasion cooperates with reduced TGF-(beta)RII signaling in tumor epithelia...
  26. doi request reprint PIK3CA-AKT pathway mutations in micropapillary breast carcinoma
    Ellen Flatley
    Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
    Hum Pathol 44:1320-7. 2013
    ..The non-micropapillary components and precursor lesions occasionally had different mutations...
  27. doi request reprint Immunohistochemical and molecular markers in breast phyllodes tumors
    Veselina B Korcheva
    Department of Pathology, L471, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    Appl Immunohistochem Mol Morphol 19:119-25. 2011
    ..The significance of the FBX4 substitution deserves further investigation...
  28. pmc KIT mutations are common in testicular seminomas
    Kathleen Kemmer
    Division of Hematology and Oncology, Oregon Health and Science University Cancer Institute and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Am J Pathol 164:305-13. 2004
    ..These findings suggest that activating KIT mutations may contribute to tumorigenesis in a subset of seminomas, but are not involved in NSGCT...
  29. ncbi request reprint BRAF in papillary thyroid carcinoma of ovary (struma ovarii)
    Jason Schmidt
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 31:1337-43. 2007
    ..In this study, we explored the possible role of these genes in the development of BSO and MSO...
  30. doi request reprint KIT gene mutations and copy number in melanoma subtypes
    Carol Beadling
    Oregon Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Clin Cancer Res 14:6821-8. 2008
    ..To determine the frequency of KIT mutations across melanoma subtypes, we surveyed a large series of tumors...
  31. ncbi request reprint Biology of gastrointestinal stromal tumors
    Christopher L Corless
    Oregon Health and Science University Cancer Institute, Department of Pathology, Portland, OR, USA
    J Clin Oncol 22:3813-25. 2004
    ..In addition, the role of mutation screening in KIT and PDGFRA as a diagnostic and prognostic aid is emphasized in this review...
  32. ncbi request reprint Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy
    Michael C Heinrich
    OHSU Cancer Institute, Oregon Health and Science University and VA Medical Center, Portland, Oregon 97239, USA
    J Surg Oncol 90:195-207; discussion 207. 2005
    ..The importance of a multi-disciplinary approach using both surgery and imatinib therapy is emphasized...
  33. ncbi request reprint PDGFRA activating mutations in gastrointestinal stromal tumors
    Michael C Heinrich
    Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
    Science 299:708-10. 2003
    ..Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs...
  34. doi request reprint Mucinous breast carcinomas lack PIK3CA and AKT1 mutations
    Elizabeth L Kehr
    Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
    Hum Pathol 43:2207-12. 2012
    ..This series represents the largest study, to date, of PIK3CA genotyping in mucinous carcinoma and supports the unique pathogenetics of invasive mucinous breast carcinoma...
  35. doi request reprint Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing
    Daphne Ang
    Department of Pathology, Oregon Health and Science University, Portland, OR, USA
    J Mol Diagn 15:312-8. 2013
    ..The novel LNA-PCR shows higher sensitivity than standard Sanger sequencing and did not amplify the known pseudogene...
  36. doi request reprint Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions
    Megan L Troxell
    Department of Pathology and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Mod Pathol 25:930-7. 2012
    ..These findings raise interesting questions about the role of PIK3CA/AKT pathway in breast carcinogenesis, and the biologic/precursor potential of columnar cell lesions...
  37. doi request reprint "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior
    Tanya A Rege
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Surg Pathol 35:495-504. 2011
    ..Although metastases are common and most tumors are imatinib resistant, they pursue a relatively indolent clinical course. Recognition of "pediatric-type" GISTs in adults is critical for prognosis, appropriate therapy, and follow-up...
  38. doi request reprint Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
    Jennifer Dunlap
    Department of Pathology, Oregon Health and Science University, L471, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA
    Breast Cancer Res Treat 120:409-18. 2010
    ....
  39. ncbi request reprint Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies
    Michael C Heinrich
    Department of Medicine, Division of Hematology Oncology, Oregon Health and Science University, USA
    J Clin Oncol 20:1692-703. 2002
    ..In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies...
  40. pmc Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma
    Shi Long Lu
    Department of Otolaryngology, OHSU Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Genes Dev 20:1331-42. 2006
    ..Our data suggest that targeting common oncogenic pathways in tumor epithelia together with blocking the effect of TGFbeta1 on tumor stroma may provide a novel therapeutic strategy for HNSCC...
  41. doi request reprint Gastrointestinal stromal tumours: origin and molecular oncology
    Christopher L Corless
    Knight Cancer Institute, Division of Haematology and Oncology, and Department of Pathology, Portland VA Medical Center and Oregon Health and Science University, Portland, OR 97239, USA
    Nat Rev Cancer 11:865-78. 2011
    ..Further improvements in GIST treatment may require targeting GIST stem cell populations and/or additional genomic events...
  42. doi request reprint Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study
    Leona A Doyle
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Histopathology 61:801-9. 2012
    ..The aim of this study was to validate the predictive value of SDHB immunohistochemistry in a large genotyped cohort...
  43. doi request reprint Biphasic papillary and lobular breast carcinoma with PIK3CA and IDH1 mutations
    Daphne Ang
    Department of Pathology, Oregon Health and Science University, Portland, USA
    Diagn Mol Pathol 21:221-4. 2012
    ..The characterization of activating point mutations in morphologic special types of breast carcinoma may suggest avenues amenable to targeted therapy...
  44. ncbi request reprint Absence of BRAF and NRAS mutations in uveal melanoma
    Frank Cruz
    Oregon Health and Science University OHSU Cancer Institute, Department of Pathology, OHSU and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Cancer Res 63:5761-6. 2003
    ..No NRAS exon 1 mutations were detected in either type of melanoma. We conclude that UMs arise independent of oncogenic BRAF and NRAS mutations, an observation that may have implications for therapies targeted to the NRAS-BRAF pathway...
  45. ncbi request reprint Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas
    Michael C Heinrich
    Department of Medicine, Oregon Health Science University Cancer Institute, Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR 97201, USA
    Cancer Treat Res 120:129-50. 2004
  46. pmc Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry
    Carol Beadling
    Division of Hematology Oncology, Oregon Health and Science University, Portland, Oregon, USA
    J Mol Diagn 13:504-13. 2011
    ..These findings demonstrate the diversity and complexity of mutations in druggable targets among the different cancer types and underscore the need for a broad-spectrum, prospective genotyping approach to personalized cancer medicine...
  47. pmc A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells
    Robert B West
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 103:690-5. 2006
    ....
  48. pmc Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia
    Terry K Morgan
    Department of Pathology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer Cytopathol 121:37-46. 2013
    ..The data from the current study indicate that a novel monoclonal antibody, HPC2 1-B3, may facilitate the diagnosis of early pancreatic dysplasia...
  49. doi request reprint BRAF and KRAS mutations in sporadic glomus tumors
    Andrea Chakrapani
    Department of Pathology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Am J Dermatopathol 34:533-5. 2012
    ..A KRAS G12A mutation was found in tumor removed from the finger. Ki-67 index did not correlate with genotype. To our knowledge, this is the first report of oncogenic mutations in sporadic glomus tumors...
  50. pmc The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status
    Robert B West
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Am J Pathol 165:107-13. 2004
    ..Reactivity for DOG1 may aid in the diagnosis of GISTs, including PDGFRA mutants that fail to express KIT antigen, and lead to appropriate treatment with imatinib mesylate, an inhibitor of the KIT tyrosine kinase...
  51. doi request reprint Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping
    Carol Beadling
    Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
    J Mol Diagn 15:171-6. 2013
    ..The rapid turnaround time and low input DNA requirements make the multiplex PCR and semiconductor-based sequencing approach a viable option for mutation detection in a clinical laboratory...
  52. doi request reprint Multiplex high-throughput gene mutation analysis in acute myeloid leukemia
    Jennifer Dunlap
    Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
    Hum Pathol 43:2167-76. 2012
    ..This approach will be helpful in defining prognostic subgroups of acute myeloid leukemia and contribute to the selection of patients for enrollment into trials with novel inhibitors...
  53. pmc KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size
    Christopher L Corless
    Department of Pathology, Division of Hematology Oncology, Oregon Health and Science University, Portland, 97201, USA
    Am J Pathol 160:1567-72. 2002
    ..The findings suggest that KIT mutations per se are of little prognostic importance in GISTs...
  54. ncbi request reprint Resistance of prostate cancer cell lines to COX-2 inhibitor treatment
    Matthew Wagner
    Division of Urology and Renal Transplantation, Oregon Health and Science University, Oregon Cancer Institute, Portland, OR, USA
    Biochem Biophys Res Commun 332:800-7. 2005
    ..In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed...
  55. ncbi request reprint Outcome following surgical therapy for gastrointestinal stromal tumors
    Maneesh Gupta
    Department of Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Gastrointest Surg 10:1099-105. 2006
    ..Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival...
  56. doi request reprint Hepatic and cardiac iron overload among patients with end-stage liver disease referred for liver transplantation
    Avital Y O'Glasser
    Division of Gastroenterology and Hepatology, Department of Medicine, Oregon Health and Science University and the Portland Veterans Affairs Medical Center, Portland, OR 97219, USA
    Clin Transplant 24:643-51. 2010
    ..Myocardial iron deposits were observed post-mortem in patients who died of cardiac events after transplantation at our institution. This observation prompted testing to exclude cardiac iron in subsequent transplant candidates...
  57. doi request reprint Frequent PIK3CA mutations in radial scars
    Katie L Wolters
    Department of Pathology Knight Cancer Institute, Oregon Health and Science University, Portland, OR
    Diagn Mol Pathol 22:210-4. 2013
    ..Additional larger studies are indicated to confirm and extend these observations in understanding the pathogenesis of radial scars and their relationship to breast cancer. ..
  58. pmc MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing Rhabdomyosarcoma
    Ken Kikuchi
    Pediatric Cancer Biology Program, Department of Pediatrics, Papé Family Pediatric Research Institute, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, Mail Code L321, Portland, OR 97239 3098, USA
    Sarcoma 2013:520858. 2013
    ..Nevertheless, MDM2 and PIK3CA are genes worthy of further investigation in patients with sclerosing rhabdomyosarcoma and might be considered in the enrollment of these patients into clinical trials of targeted therapeutics...
  59. ncbi request reprint Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer
    Eugene Y Chang
    Department of Surgery, Oregon Health and Science University, Mail Code L223A, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    Am J Surg 193:614-7; discussion 617. 2007
    ..We hypothesized that routine pathologic examination fails to identify some residual cancer...
  60. ncbi request reprint Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants
    Susan L Orloff
    Portland Veterans Affairs Medical Center, Portland, Oregon 97201, USA
    Transplantation 73:679-88. 2002
    ..This study examined the role of CMV and the alloreactive response in the development of TVS using bone marrow chimerism (BMC) in rat small bowel (SB) and heart transplantation models...
  61. ncbi request reprint Immunosuppression impact on long-term cardiovascular complications after liver transplantation
    John M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd L590, Portland, Oregon 97201 3098, USA
    Am J Surg 183:595-9. 2002
    ..Cardiovascular disease and associated risk factors have been shown in renal transplant patients to be related to the pharmacologic immunosuppression employed...
  62. ncbi request reprint Experimental percutaneous extrahepatic portacaval shunt creation by transjugular approach in Swine
    Chang Kyu Seong
    Dotter Interventional Institute, Oregon Health and Science University, L342, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Cardiovasc Intervent Radiol 28:616-23. 2005
    ..None of the tested rigid stent-grafts were suitable for PEPS creation. A short flexible stent-graft with flanged ends is suggested for further exploration...
  63. ncbi request reprint Percutaneous bioprosthetic venous valve: a long-term study in sheep
    Dusan Pavcnik
    Dotter Interventional Institute, Oregon Health Sciences University and Portland Veterans Administration Medical Center, 97201, USA
    J Vasc Surg 35:598-602. 2002
    ..Slight to moderate leaflet thickening was found mostly at their bases. Percutaneously placed SIS BVV is a promising one-way, competent valve that resists venous back-pressure while allowing forward flow...
  64. pmc The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma
    Jody E Hooper
    Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
    Hum Pathol 43:1583-9. 2012
    ..01). The combination of both markers provided even better specificity and positive likelihood ratios. We conclude that HPC2 and N-cadherin significantly improve accurate classification of pancreatic cancer and cholangiocarcinoma...
  65. ncbi request reprint In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors
    Gayathri R Devi
    AVI BioPharma, Inc, Corvallis, Oregon and Oregon Health and Science University Cancer Institute, Portland, Oregon, USA
    Clin Cancer Res 11:3930-8. 2005
    ..Data from both human studies indicated similar plasma concentration-time profile. These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials...
  66. ncbi request reprint State-of-the art therapy for gastrointestinal stromal tumors
    Charles D Blanke
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Cancer Invest 23:274-80. 2005
    ..Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance...
  67. ncbi request reprint Percutaneous vein occlusion with small intestinal submucosa: an experimental pilot study in Swine and sheep
    Man Deuk Kim
    Dotter Interventional Institute, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Cardiovasc Intervent Radiol 30:725-30. 2007
    ..Our hypothesis was that SIS would cause vein occlusion...
  68. pmc Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants
    Daniel N Streblow
    Departments of Molecular Microbiology, Oregon Health Sciences University, Portland, Oregon 97201, USA
    J Virol 77:2182-94. 2003
    ..These results suggest that CMV-induced acceleration of TVS involves the increased graft vascular infiltration of inflammatory cells through enhanced chemokine expression...
  69. pmc A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer
    Jacob Schwartzman
    Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Epigenetics 6:1248-56. 2011
    ..These results demonstrate that bead arrays offer a high-throughput method to discover novel genes with promoter DNA methylation such as ERG, whose measurement may improve our ability to more accurately detect prostate cancer...
  70. ncbi request reprint Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, CR 145, Portland, OR 97239, USA
    Cancer Epidemiol Biomarkers Prev 13:2225-32. 2004
    ..In this study, we selected this approach to test several hypotheses about the effect of calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D, on early-stage human prostate cancer...
  71. doi request reprint Protein kinase A RII-like (R2D2) proteins exhibit differential localization and AKAP interaction
    Amy E Hanlon Newell
    VA Medical Center and Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
    Cell Motil Cytoskeleton 65:539-52. 2008
    ..Based on location, affinity for AKAPs and lack of affinity for cAMP, it appears that each R2D2 protein has a unique role in this process...
  72. ncbi request reprint Sentinel node staging of primary melanoma by the "10% rule": pathology and clinical outcomes
    Rachel E Emery
    School of Medicine, L109 Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Am J Surg 193:618-22; discussion 622. 2007
    ..Although some suggest removal of only the "hottest" SLN, the "10% rule" dictates that nodes are removed until the background count is 10% or less of the count of the "hottest" node...
  73. ncbi request reprint The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas
    Vassil Kaimaktchiev
    OHSU Cancer Institute and Department of Pathology, Oregon Health and Science University, Portland, OR 97239, USA
    Mod Pathol 17:1392-9. 2004
    ..CDX2 may also be helpful in distinguishing adenocarcinomas of the ampulla from those arising in the pancreas and biliary tree...
  74. ncbi request reprint Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients
    Atif Zaman
    Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Am J Med 120:280.e9-14. 2007
    ..Our objective was to prospectively validate a panel of serum fibrosis markers (FIBROSpect(SM) II) that has been recently developed...
  75. ncbi request reprint Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation
    Shi Long Lu
    Department of Otolaryngology, Oregon Health and Science University, Portland, USA
    Cancer Res 64:4405-10. 2004
    ..These phenotypes correlated with enhanced Smad signaling in transgenic epithelia and stroma. Our study suggests that TGF-beta1 overexpression at early stages of HNSCC formation provides a tumor promoting microenvironment...
  76. doi request reprint Distinctive morphology of renal cell carcinomas in tuberous sclerosis
    Andrew Schreiner
    Department of Pathology, Division of Urology and Renal Transplantation, Oregon Health and Science University, Portland, OR 97239, USA
    Int J Surg Pathol 18:409-18. 2010
    ..The histopathological features of these carcinomas illustrate characteristics of renal carcinoma that are probably related to genetic alterations of tuberous sclerosis...
  77. ncbi request reprint Effects of blood flow and/or ventilation restriction on radiofrequency coagulation size in the lung: an experimental study in swine
    Hiroshi Anai
    Dotter Interventional Institute, Oregon Health and Science University, Portland, Oregon 97201 3098, USA
    Cardiovasc Intervent Radiol 29:838-45. 2006
    ..The value of these restrictions for potential clinical use needs to be explored in experimentally induced lung tumors...
  78. pmc The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase
    Vladimir Vartanian
    Center for Research on Occupational and Environmental Toxicology and Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Proc Natl Acad Sci U S A 103:1864-9. 2006
    ..These data suggest an important role for NEIL1 in the prevention of the diseases associated with the metabolic syndrome...
  79. doi request reprint The value of traditional upper endoscopy as a diagnostic test for Barrett's esophagus
    Amy Wang
    Department of Gastroenterology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Gastrointest Endosc 68:859-66. 2008
    ..The standard test for diagnosing Barrett's esophagus (BE) is a conventional upper endoscopy. However, studies have shown that confirmation of BE by endoscopy with histologic intestinal metaplasia can be difficult...
  80. ncbi request reprint Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation
    Deepak V Gopal
    Division of Gastroenterology and Hepatology, Oregon Health Sciences University and Portland VA Medical Center, Portland, Oregon 97207, USA
    J Clin Gastroenterol 37:344-7. 2003
    ..Most reports of PSC recurrence post-OLT estimate rates of 1% to 14%, but to date, no center has reported rapidly progressive fibro-obliterative cholangitis leading to graft failure...
  81. ncbi request reprint High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure
    Jason D Estes
    Division of Liver Pancreas Transplantation, Oregon Health and Science University, Portland, OR 97201, USA
    Arch Surg 138:852-8. 2003
    ..The use of potentially hepatotoxic herbal and dietary supplements is highly prevalent in the fulminant hepatic failure (FHF) patient population at our institution, and this subgroup of patients has a worse prognosis...
  82. ncbi request reprint Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)
    John K Petty
    Department of Surgery, Section of Surgical Oncology, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, L223A, Portland, OR 97201 3098, USA
    Am J Surg 183:512-8. 2002
    ..The T-cell costimulatory molecule OX-40 (CD134) is expressed on activated CD4(+) ("helper") T cells. Such cells have been detected in human cancers, and engagement of OX-40 improves colon cancer immunity in an animal model...
  83. pmc Transplanted human bone marrow contributes to vascular endothelium
    Shuguang Jiang
    Center for Hematologic Malignancies, Division of Hematology and Medical Oncology, Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
    Proc Natl Acad Sci U S A 101:16891-6. 2004
    ..Transplantable bone marrow-derived endothelial progenitor cells may represent novel therapeutic targets for hematopoietic and vascular disease...
  84. pmc KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?
    Jonathan A Fletcher
    Am J Pathol 161:737-8; author reply 738-9. 2002
  85. ncbi request reprint Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
    Jayesh Desai
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:5398-405. 2007
    ..The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression...
  86. ncbi request reprint Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation
    Janet Graham
    Beatson Oncology Centre, Glasgow, United Kingdom
    Arch Pathol Lab Med 131:1393-6. 2007
    ..To our knowledge, this is only the second germline example of this particular mutation. The patient's esophageal tumors were stabilized with imatinib...
  87. ncbi request reprint Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs
    Saad F Jazrawi
    Liver Transplantation Program, the Division of Gastroenterology Hepatology, Portland Veterans Administration Medical Center, OR 97207, USA
    Liver Transpl 9:377-82. 2003
    ..In this large case control analysis of patients undergoing liver transplantation for diverse etiologies, TNF promoter polymorphisms were not independently associated with rejection or survival...
  88. ncbi request reprint Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT
    Sebastian Bauer
    Department of Internal Medicine Cancer Research, University of Essen Medical School, Germany
    Cancer Chemother Pharmacol 51:261-5. 2003
    ..Our experience with this patient suggests that even GISTs with very low levels of KIT expression may respond to imatinib mesylate therapy...
  89. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  90. ncbi request reprint Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization
    Abbas Agaimy
    Institute of Pathology, Klinikum Nürnberg, 90419 Nurnberg, Germany
    Oncol Rep 18:9-15. 2007
    ....
  91. ncbi request reprint Gastrointestinal stromal tumour
    Brian P Rubin
    Department of Anatomic Pathology, Taussig Cancer Center and the Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Lancet 369:1731-41. 2007
    ..The important interplay between the molecular genetics of gastrontestinal stromal tumour and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumours...
  92. ncbi request reprint Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testing
    Christopher L Corless
    Am J Clin Pathol 122:11-3. 2004
  93. ncbi request reprint Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features
    Ciarán O'Riain
    Department of Histopathology, St Vincent s University Hospital, Elm Park, Dublin, Ireland
    Am J Surg Pathol 29:1680-3. 2005
    ..Two smaller lesions from this patient were heterozygous for the mutation. This phenomenon has been observed in up to 8% of sporadic malignant GISTs but has not been documented in familial disease...
  94. ncbi request reprint Comparison of the endothelialization of small intestinal submucosa, dacron, and expanded polytetrafluoroethylene suspended in the thoracoabdominal aorta in sheep
    Kivilcim Yavuz
    Department of Radiology, Royal Perth Hospital, Perth, Australia
    J Vasc Interv Radiol 17:873-82. 2006
    ....
  95. ncbi request reprint Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT
    Lawrence H Einhorn
    Department of Medicine, Division of Hematology Oncology, Indiana University, Indianapolis, Indiana and Walther Cancer Institute, Indianapolis, IN, USA
    Am J Clin Oncol 29:12-3. 2006
    ..This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor...
  96. doi request reprint Major response to imatinib mesylate in KIT-mutated melanoma
    F Stephen Hodi
    The Melanoma Program, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 26:2046-51. 2008
  97. doi request reprint Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases
    Jerzy Lasota
    Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Mod Pathol 21:476-84. 2008
    ..The latter is also true for all KIT exon 17 mutant GISTs...
  98. pmc Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1
    Douglas R Stewart
    J Med Genet 44:e61. 2007
    ..Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours that commonly harbour oncogenic mutations in KIT or PDGFRA and are thought to arise from the interstitial cells of Cajal (ICC; the pacemaker cells of the gut)...
  99. ncbi request reprint Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225
    Grant A McArthur
    Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Clin Oncol 23:866-73. 2005
    ..The purpose of this study was to evaluate molecular, cytogenetic, and kinase activation profiles in a series of DFSPs and to determine whether these biologic parameters are correlated with the clinical responses of DFSP to imatinib...
  100. ncbi request reprint Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors
    Katherine A Janeway
    Department of Medicine, Children s Hospital Boston, MA, USA
    Cancer Res 67:9084-8. 2007
    ..KIT activation levels in pediatric KIT-wild-type GISTs are comparable with those in KIT-mutant GISTs. Therapies that inhibit KIT activation, or crucial KIT signaling intermediates, should be explored in pediatric KIT-wild-type GIST...
  101. pmc Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach
    Robert J Coffey
    Department of Medicine, Vanderbilt University Medical Center and Nashville Veterans Affairs Medical Center, Nashville, Tennessee, USA
    J Clin Invest 117:70-80. 2007
    ....